The purpose of this study is to evaluate how effective cemiplimab is as a maintenance treatment for patients with advanced adrenocortical carcinoma who have not shown disease progression after initial treatment. Participants in the study will receive cemiplimab through an intravenous infusion, which means the medication is given directly into a vein. The study will also include a comparison with a placebo to assess the effectiveness of the treatment. The trial will last for a period of up to 36 months, during which participants will have regular clinic visits to monitor their health and the effects of the treatment.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The main goal is to see if cemiplimab can help prevent the cancer from getting worse and to understand its impact on the overall quality of life and survival of the patients. The study will also collect information on any adverse effects experienced by participants to ensure the safety and effectiveness of the treatment. This research aims to provide valuable insights into the potential benefits of cemiplimab for individuals with advanced adrenocortical carcinoma.

The purpose of this study is to assess how well the combination of these treatments works in patients with advanced or metastatic adrenocortical carcinoma, meaning the cancer has spread to other parts of the body. Participants will be randomly assigned to receive either the combination of chemotherapy with progesterone or chemotherapy with a placebo. The study will monitor the participants over a period to see how the cancer responds to the treatment.

Throughout the study, participants will receive regular medical check-ups and monitoring to ensure their safety and to track the progress of the treatment. The study is designed to provide valuable information on whether adding progesterone to the standard chemotherapy regimen can improve outcomes for patients with this challenging form of cancer.

Participants in the study will receive pembrolizumab, which is given as an injection into a vein. The study will monitor how the cancer responds to the treatment over time, including whether the cancer shrinks or stops growing. The study will also look at how long patients live without the cancer getting worse and how long any positive effects of the treatment last. Additionally, the study will assess the overall survival of patients and their quality of life during the treatment.

Throughout the study, researchers will keep track of any side effects or adverse events that participants may experience, whether they are related to the treatment or not. The study aims to provide valuable information about the potential benefits and risks of using pembrolizumab for treating advanced adrenocortical carcinoma, which could help improve future treatment options for this challenging condition.

The purpose of this study is to compare how well mitotane alone works compared to mitotane combined with cisplatin and etoposide in preventing the cancer from returning after surgery. Patients in the combination treatment group will receive four cycles of chemotherapy, with each cycle lasting 21 days, alongside their mitotane therapy. Throughout the study, participants will have regular check-ups that include physical examinations, blood tests to monitor general health and hormone levels, and imaging scans such as CT scans with contrast medium, MRI, or PET-CT scans to check for any signs of cancer recurrence. These imaging tests use different technologies to create detailed pictures of the inside of the body to detect any abnormal changes.

During the study, researchers will also evaluate how blood levels of mitotane, the stage of disease, certain tumor characteristics, and the completeness of surgical removal affect treatment outcomes. The study will assess how the timing of starting treatment after surgery may influence results, and participants will be asked to complete questionnaires about their quality of life at several time points. Safety will be carefully monitored by tracking any serious side effects that occur during treatment and for one year after treatment ends.